For providers
Riskguard® Hereditary Cancer Test

The Riskguard® test helps you help your patients

The Riskguard® test is an assessment tool that can help uncover variants associated with an increased risk of common hereditary cancers and cancer-related syndromes. The actionable results can help you better understand your patients’ risk levels and management options, supporting personalized care.
A health care provider with stethoscope talking to a patient.
Gauge cancer risk to inform treatment and risk-management4-9
New York state-approved
Covered by Medicare and many commercial insurance plans*
A health care provider with stethoscope talking to a patient.

Gene panel

Evaluates 59 genes across 11 common cancer types. View the technical specifications or visit the Gene Information page to learn more.

Specimen requirements

3-5mL of blood collected in an EDTA tube, saliva sample or buccal (cheek) swab. See the specimen collection instructions.

Turnaround time

You should receive patient results approximately 14 to 21† days from sample receipt.
An older woman smiling and holding a baby, interacting with an older man and a younger woman.
Approximately 1 in 8 cancers are due to a hereditary cancer syndrome.1

Harness the power of genetic insights to help personalize treatment and risk-management4-9

The Riskguard test can help patients with a personal or family history of cancer understand their risk of developing certain cancers, which can inform screening, treatment, and risks to family members. Actionable results offer insight into risk level and management options, leading to more personalized care.
A younger man in glasses, kissing the head of an older woman who is smiling.

Hereditary cancer is common

Hereditary cancers, which account for approximately 10-15% of cancer diagnoses, are caused by pathogenic germline variants and are often associated with early onset cancer, aggressive forms of cancer, and multiple cancer diagnoses in an individual and/or family.1

A health care provider with stethoscope placing her hand on a patient’s shoulder.

Testing is under-utilized

It is estimated that only 7% of patients with cancer have received germline genetic testing,2 which could inform treatment. And the majority of both diagnosed and undiagnosed patients do not regret undergoing testing and are interested in learning all results from germline genetic testing.3

The Riskguard test checks 59 genes across 11 common cancer types

Approximately 1 in 8 cancers are due to a hereditary syndrome.1 The Riskguard test helps patients learn more about their genetic risk for some of the most common and aggressive cancer types.

Colorectal     Breast     Prostate     Pancreatic     Ovarian     Endometrial     Skin     Gastric     Kidney     Endocrine     Lung

A lab technician examining a vial of blood.

Who can the Riskguard test help?

A man and woman sitting together with their eyes closed, holding hands.

Patients without cancer

The Riskguard test helps inform the risk stratification for patients who have a family history of cancer by identifying variants in clinically actionable cancer-associated genes, which may inform a customized care path.

Customize a risk-management path

  • Lifestyle changes
  • Screening programs
  • Risk-reducing medication
  • Risk-reducing surgeries
A blonde woman looking off to the distance.

Patients with cancer

The Riskguard test can assist with informing an individualized plan for your patients who have been diagnosed with cancer. Knowing about certain gene variants can help you select optimal treatment.4-9

Inform optimal treatment

  • Surgical options
  • Increased surveillance
  • Targeted therapies
A surgeon performing surgery, wearing a cap and mask.

Faster genetic insights for informed surgical decisions

Get expedited results from nine high-risk cancer genes in just 7-10 days when you order the STAT Breast Cancer Panel with the Riskguard® test.

  • Fast turnaround time
  • Results that could inform clinical intervention
  • Easy to order in the Exact Sciences Provider Hub

More ways to personalize patient care

Pair the Riskguard test with our Oncotype DX Breast Recurrence Score® test to help inform a more comprehensive treatment plan for newly diagnosed ER+/HER2- breast cancer.

Add the Riskguard test with our OncoExTra® genomic profiling test to enable more patients with advanced or metastatic cancer to be considered for targeted therapies.

We keep it simple and actionable

We want our results to be simple yet powerful. That's why we only evaluate genes in which a positive result can lead to action based on guidelines and published literature. We provide easy-to-understand results that providers and patients can use to assist with personalized care planning.

Negative sample report

PDF

Positive sample report

PDF

Uncertain sample report

PDF
A healthcare provider in white lab coat typing on a laptop.

Complete access to our premium customer support before, during, and after testing

On-demand customer care

Call our customer care team for general questions. You can request Riskguard test kits, and ask about billing, ordering, and how to access results.

Call +1 866-662-6897

Genetic support for your patients

Our team of genetic counselors is available to answer questions you might have about the genetic testing process. If needed, we can connect patients with third-party genetic counseling services for a full consultation with our trusted partner, Genome Medical.‡

Genetic support for you

Ask customer care to connect you with one of our genetic counselors for an in-depth consult. We can help you understand and interpret Riskguard test results, including medical management options for your patient.

Patient education on demand

Want to help your patients learn about the Riskguard test? Genetic Counselor Brandie Leach breaks down who the test is for, what the testing process is like, and how the results could inform your risks.
Video thumbnail.
Is the Riskguard test right for your patient?
Your patients may be candidates for the Riskguard test if they meet any of the following criteria.
Rare cancers
The Riskguard test is appropriate for patients with rare cancers. Examples include patients with ovarian cancer, pancreatic cancer or male breast cancer.10-12
Multiple cancers
Patients with multiple primary breast cancers, or synchronous or metachronous Lynch Syndrome (LS)-related cancers§ are good candidates for the Riskguard test.10,13
Cancer at an early age
If your patient was diagnosed with breast cancer ≤ 50 years of age, colorectal cancer < 50 years of age or endometrial cancer < 50 years of age, they are a candidate.10,13
Cancer with specific traits
Consider the Riskguard test if your patient has triple-negative breast cancer, a tumor with mismatch repair deficiency, metastatic breast or prostate cancer, or breast or prostate cancer and they have Ashkenazi ancestry.10,13,14

Billing is easy when you have a support team like ours

  • Coverage for eligible patients including Medicare and commercial insurance*
  • Specialized support for billing insurance and prior authorization
  • Flexible payment options for patients
A smiling man looking down at a mobile device.
Provider resources
Download patient studies, screening tools, educational guides, and more.
A healthcare provider on a tablet speaking with a patient.

Ordering a test for your patients is fast and easy

Order tests, access results, and receive updates through our Provider Hub.

We're here for you

With questions about ordering the Riskguard test, insurance billing and payment options, checking results, or getting connected with a genetic counselor, call us at +1 866-662-6897 or email us at riskguard@exactsciences.com.

Loading component...

The Exact Sciences Riskguard test was developed, and its performance characteristics validated by an Exact Sciences laboratory following College of American Pathologists (CAP) and Clinical Laboratory Improvement Amendments (CLIA) regulations. The test is performed in Marshfield, WI at PreventionGenetics LLC, a wholly owned subsidiary of Exact Sciences. PreventionGenetics is accredited by CAP, certified under CLIA regulations, and qualified to perform high-complexity clinical laboratory testing. It has not been cleared or approved by the US Food and Drug Administration or other notified regulatory authority. Genomic Health, Inc., an Exact Sciences company, is the billing entity for the Riskguard test.